Cannabinoid CB1 receptor antagonists as potential pharmacotherapies for drug abuse disorders

International Review of Psychiatry

Volumn 21, Issue 2 SPEC. ISS., 2009, Pages 134-142

  Beardsley, Patrick M ^a   Thomas, Brian F ^b   Mcmahon, Lance R ^c  

^a VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

^b RTI INTERNATIONAL   (United States)

^c UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1 (2,4 DICHLOROPHENYL) 5 (4 IODOPHENYL) 4 METHYL N (1 PIPERIDYL) 1H PYRAZOLE 3 CARBOXAMIDE; 5 (4 BROMOPHENYL) 1 (2,4 DICHLOROPHENYL) 4 ETHYL N (1 PIPERIDYL) 1H PYRAZOLE 3 CARBOXAMIDE; CANNABINOID 1 RECEPTOR; CANNABINOID 1 RECEPTOR ANTAGONIST; CAPSAZEPINE; CYCLOHEXYLCARBAMIC ACID 3' CARBAMOYLBIPHENYL 3 YL ESTER; DRONABINOL; MECAMYLAMINE; NICOTINE; PLACEBO; RIMONABANT;

ALCOHOLISM; CLINICAL TRIAL; COCAINE DEPENDENCE; DRUG ANTAGONISM; DRUG DEPENDENCE; DRUG DOSE REDUCTION; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; DRUG MEGADOSE; DRUG WITHDRAWAL; HUMAN; NAUSEA; NONHUMAN; OPIATE ADDICTION; PRIORITY JOURNAL; REVIEW; TOBACCO DEPENDENCE; WITHDRAWAL SYNDROME;

ANIMALS; BRAIN; DOPAMINE; HUMANS; NEURAL PATHWAYS; PIPERIDINES; PYRAZOLES; RECEPTOR, CANNABINOID, CB1; REWARD; SUBSTANCE-RELATED DISORDERS;

EID: 67651037622     PISSN: 09540261     EISSN: 13691627     Source Type: Journal    
DOI: 10.1080/09540260902782786     Document Type: Review

References (76)

1. Aceto, M.D., Scates, S.M., Lowe, J.A., & Martin, B.R. (1996). Dependence on delta 9-tetrahydrocannabinol: Studies on precipitated and abrupt withdrawal. Journal of Pharmacology and Experimental Therapeutics, 278, 1290-1295.
2. Aceto, M.D., Scates, S.M., & Martin, B.B. (2001). Spontaneous and precipitated withdrawal with a synthetic cannabinoid, WIN 55212-2. European Journal of Pharmacology, 416, 75-81.
3. Anggadiredja, K., Nakamichi, M., Hiranita, T., Tanaka, H., Shoyama, Y., Watanabe, S. et al. (2004). Endocannabinoid system modulates relapse to methamphetamine seeking: Possible mediation by the arachidonic acid cascade. Neuropsychopharmacology, 29, 1470-1478.
4. Anthenelli, R.M., & Despres, J.-P. (2004). Effects of rimonabant in the reduction of major cardiovascular risk factors. Results from the STRATUS-US Trial (Smoking Cessation in Smokers Motivated to Quit) and the RIO-LIPIDS Trial (Weight Reducing and Metabolic Effects in Overweight/Obese Patients with Dyslipidemia), Paper delivered at the 53rd Annual American College of Cardiology Scientific Session, New Orleans, March 2004.
5. Arnone, M., Maruani, J., Chaperon, F., Thiebot, M.H., Poncelet, M., Soubrie, P. et al. (1997). Selective inhibition of sucrose and ethanol intake by SR 141716, an antagonist of central cannabinoid (CB1) receptors. Psychopharmacology, 132, 104-106.
6. Balerio, G.N., Aso, E., Berrendero, F., Murtra, P., & Maldonado, R. (2004). Delta9-tetrahydrocannabinol decreases somatic and motivational manifestations of nicotine withdrawal in mice. European Journal of Neuroscience, 20, 2737-2748.
7. Bass, C.E., Griffin, G., Grier, M., Mahadevan, A., Razdan, R.K., & Martin, B.R. (2002). SR-141716A-induced stimulation of locomotor activity. A structure-activity relationship study. Pharmacology, Biochemistry and Behavior, 74, 31-40.
8. Beardsley, P.M., & Thomas, B.F. (2005). Current evidence supporting a role of cannabinoid CB1 receptor (CB1R) antagonists as potential pharmacotherapies for drug abuse disorders. Behavioural Pharmacology, 16, 275-296.
9. Boctor, S.Y., Martinez Jr, J.L., Koek, W., & France, C.P. (2007). The cannabinoid CB1 receptor antagonist AM251 does not modify methamphetamine reinstatement of responding. European Journal of Pharmacology, 571, 39-43.
10. Braida, D., Pozzi, M., Parolaro, D., & Sala, M. (2001). Intracerebral self-administration of the cannabinoid receptor agonist CP 55,940 in the rat: Interaction with the opioid system. European Journal of Pharmacology, 413, 227-234.
11. Cahill, K., & Ussher, M. (2007). Cannabinoid type 1 receptor antagonists (rimonabant) for smoking cessation. Cochrane Database Systematic Reviews Issue 4. Art No.: CD005353. DOI: 10.1002/14651858.CD005353.pub 3.
12. Caille, S., & Parsons, L.H. (2003). SR141716A reduces the reinforcing properties of heroin but not heroin-induced increases in nucleus accumbens dopamine in rats. European Journal of Neuroscience, 18, 3145-3149.
13. Castañé, A., Valjent, E., Ledent, C., Parmentier, M., Maldonado, R., & Valverde, O. (2002). Lack of CB1 cannabinoid receptors modifies nicotine behavioural responses, but not nicotine abstinence. Neuropharmacology, 43, 857-867.
14. Chaperon, F., Soubrie, P., Puech, A.J., & Thiebot, M.H. (1998). Involvement of central cannabinoid (CB1) receptors in the establishment of place conditioning in rats. Psychopharmacology, 135, 324-332.
15. Chiang, Y.C., & Chen, J.C. (2007). The role of the cannabinoid type 1 receptor and down-stream cAMP/DARPP-32 signal in the nucleus accumbens of methamphetamine-sensitized rats. Journal of Neurochemistry, 103, 2505-2517.
16. Cippitelli, A., Bilbao, A., Hansson, A.C., del Arco, I., Sommer, W., Heilig, M. et al. (2005). Cannabinoid CB1 receptor antagonism reduces conditioned reinstatement of ethanol-seeking behavior in rats. European Journal of Neuroscience, 21, 2243-2251.
17. Cohen, C., Perrault, G., Griebel, G., & Soubrie, P. (2005). Nicotine-associated cues maintain nicotine-seeking behavior in rats several weeks after nicotine withdrawal: Reversal by the cannabinoid (CB1) receptor antagonist, rimonabant (SR141716). Neuropsychopharmacology, 30, 145-155.
18. Cohen, C., Perrault, G., Voltz, C., Steinberg, R., & Soubrie, P. (2002). SR141716, a central cannabinoid (CB(1)) receptor antagonist, blocks the motivational and dopamine-releasing effects of nicotine in rats. Behavioural Pharmacology, 13, 451-463.
19. Colombo, G., Vacca, G., Serra, S., Carai, M.A., & Gessa, G.L. (2004). Suppressing effect of the cannabinoid CB1 receptor antagonist, SR 141716, on alcohol's motivational properties in alcohol-preferring rats. European Journal of Pharmacology, 498, 119-123.
20. Corbille, A.G., Valjent, E., Marsicano, G., Ledent, C., Lutz, B., Herve, D. et al. (2007). Role of cannabinoid type 1 receptors in locomotor activity and striatal signaling in response to psychostimulants. Journal of Neuroscience, 27, 6937-6947.
21. Cossu, G., Ledent, C., Fattore, L., Imperato, A., Bohme, G.A., Parmentier, M. et al. (2001). Cannabinoid CB1 receptor knockout mice fail to self-administer morphine but not other drugs of abuse. Behavioural Brain Research, 118, 61-65.
22. Cramois, N., & Podvin, J.-M. (2004). Two pivotal studies indicate Acomplia™ (Rimonabant) offers a novel approach to cardiovascular risk management in overweight/obese people and smokers. (Sanofi-synthelabo, press release), American College of Cardiology Annual Meeting, New Orleans.
23. De Vries, T.J., de Vries, W., Janssen, M.C., & Schoffelmeer, A.N. (2005). Suppression of conditioned nicotine and sucrose seeking by the cannabinoid-1 receptor antagonist SR141716A. Behavioural Brain Research, 161, 164-168.
24. De Vries, T.J., Homberg, J.R., Binnekade, R., Raaso, H., & Schoffelmeer, A.N. (2003). Cannabinoid modulation of the reinforcing and motivational properties of heroin and heroin-associated cues in rats. Psychopharmacology, 168, 164-169.
25. De Vries, T.J., Shaham, Y., Homberg, J.R., Crombag, H., Schuurman, K., Dieben, J. et al. (2001). A cannabinoid mechanism in relapse to cocaine seeking. Nature Medicine, 7, 1151-1154.
26. Diergaarde, L., de Vries, W., Raaso, H., Schoffelmeer, A.N., & De Vries, T.J. (2008). Contextual renewal of nicotine seeking in rats and its suppression by the cannabinoid-1 receptor antagonist rimonabant (SR141716A). Neuropharmacology, 55, 712-716.
27. Dyr, W., Ligieza, J., & Kostowski, W. (2008). The effect of cannabinoid CB(1) receptor antagonist rimonabant (SR-141716) on ethanol drinking in high-preferring rats. Alcohol, 42, 509-512.
28. Economidou, D., Mattioli, L., Cifani, C., Perfumi, M., Massi, M., Cuomo, V. et al. (2006). Effect of the cannabinoid CB1 receptor antagonist SR-141716A on ethanol self-administration and ethanol-seeking behaviour in rats. Psychopharmacology, 183, 394-403.
29. Fattore, L., Martellotta, M.C., Cossu, G., Mascia, M.S., & Fratta, W. (1999). CB1 cannabinoid receptor agonist WIN 55,212-2 decreases intravenous cocaine self-administration in rats. Behavioural Brain Research, 104, 141-146.
30. Fattore, L., Spano, M.S., Cossu, G., Deiana, S., & Fratta, W. (2003). Cannabinoid mechanism in reinstatement of heroin-seeking after a long period of abstinence in rats. European Journal of Neuroscience, 17, 1723-1726.
31. Forget, B., Barthelemy, S., Saurini, F., Hamon, M., & Thiebot, M.H. (2006). Differential involvement of the endo-cannabinoid system in short- and long-term expression of incentive learning supported by nicotine in rats. Psychopharmacology, 189, 59-69.
32. Forget, B., Hamon, M., & Thiebot, M.H. (2005). Cannabinoid CB1 receptors are involved in motivational effects of nicotine in rats. Psychopharmacology, 181, 722-734.
33. Freedland, C.S., Poston, J.S., & Porrino, L.J. (2000). Effects of SR141716A, a central cannabinoid receptor antagonist, on food-maintained responding. Pharmacology, Biochemistry and Behavior, 67, 265-270.
34. Freedland, C.S., Sharpe, A.L., Samson, H.H., & Porrino, L.J. (2001). Effects of SR141716A on ethanol and sucrose self-administration. Alcoholism, Clinical and Experimental Research, 25, 277-282.
35. Gallate, J.E., & McGregor, I.S. (1999). The motivation for beer in rats: Effects of ritanserin, naloxone and SR 141716. Psychopharmacology, 142, 302-308.
36. Gerdeman, G.L., Schechter, J.B., & French, E.D. (2008). Context-specific reversal of cocaine sensitization by the CB(1) cannabinoid receptor antagonist rimonabant. Neuropsychopharmacology, 33, 2747-2759.
37. Gessa, G.L., Serra, S., Vacca, G., Carai, M.A., & Colombo, G. (2005). Suppressing effect of the cannabinoid CB1 receptor antagonist, SR147778, on alcohol intake and motivational properties of alcohol in alcohol-preferring sP rats. Alcohol and Alcoholism, 40, 46-53.
38. Ginsburg, B.C., & Lamb, R.J. (2006). Cannabinoid effects on behaviors maintained by ethanol or food: A within-subjects comparison. Behavioural Pharmacology, 17, 249-257.
39. Hiranita, T., Nawata, Y., Sakimura, K., & Yamamoto, T. (2008). Methamphetamine-seeking behavior is due to inhibition of nicotinic cholinergic transmission by activation of cannabinoid CB1 receptors. Neuropharmacology, 55, 1300-1306.
40. Kauer, J.A., & Malenka, R.C. (2007). Synaptic plasticity and addiction. Nature Reviews Neuroscience, 8, 844-858.
41. Kirkham, T.C., Williams, C.M., Fezza, F., & Di Marzo, V. (2002). Endocannabinoid levels in rat limbic forebrain and hypothalamus in relation to fasting, feeding and satiation: Stimulation of eating by 2-arachidonoyl glycerol. British Journal of Pharmacology, 136, 550-557.
42. Kobilo, T., Hazvi, S., & Dudai, Y. (2007). Role of cortical cannabinoid CB1 receptor in conditioned taste aversion memory. European Journal of Neuroscience, 25, 3417-3421.
43. Kodas, E., Cohen, C., Louis, C., & Griebel, G. (2007). Corticolimbic circuitry for conditioned nicotine-seeking behavior in rats involves endocannabinoid signaling. Psychopharmacology, 194, 161-171.
44. Lallemand, F., & De Witte, P. (2006). SR147778, a CB1 cannabinoid receptor antagonist, suppresses ethanol preference in chronically alcoholized Wistar rats. Alcohol, 39, 125-134.
45. Lallemand, F., Soubrie, P., & De Witte, P. (2004). Effects of CB1 cannabinoid receptor blockade on ethanol preference after chronic alcohol administration combined with repeated re-exposures and withdrawals. Alcohol and Alcoholism, 39, 486-492.
46. Lallemand, F., Soubrie, P.H., & De Witte, P.H. (2001). Effects of CB1 cannabinoid receptor blockade on ethanol preference after chronic ethanol administration. Alcoholism, Clinical and Experimental Research, 25, 1317-1323.
47. Le Foll, B., & Goldberg, S.R. (2004). Rimonabant, a CB1 antagonist, blocks nicotine-conditioned place preferences. Neuroreport, 15, 2139-2143.
48. Lesscher, H.M., Hoogveld, E., Burbach, J.P., van Ree, J.M., & Gerrits, M.A. (2005). Endogenous cannabinoids are not involved in cocaine reinforcement and development of cocaine-induced behavioural sensitization. European Neuropsychopharmacology, 15, 31-37.
49. Lichtman, A.H., Sheikh, S.M., Loh, H.H., & Martin, B.R. (2001). Opioid and cannabinoid modulation of precipitated withdrawal in delta(9)-tetrahydrocannabinol and morphinedependent mice. Journal of Pharmacology and Experimental Therapeutics, 298, 1007-1014.
50. Lopez-Moreno, J.A., Gonzalez-Cuevas, G., & Navarro, M. (2006). The CB1 cannabinoid receptor antagonist rimonabant chronically prevents the nicotine-induced relapse to alcohol. Neurobiology of Disease, 25, 274-283.
51. Lupica, C.R., & Riegel, A.C. (2005). Endocannabinoid release from midbrain dopamine neurons: A potential substrate for cannabinoid receptor antagonist treatment of addiction. Neuropharmacology, 48, 1105-1116.
52. Mas-Nieto, M., Pommier, B., Tzavara, E.T., Caneparo, A., Da Nascimento, S., Le Fur, G. et al. (2001). Reduction of opioid dependence by the CB(1) antagonist SR141716A in mice: Evaluation of the interest in pharmacotherapy of opioid addiction. British Journal of Pharmacology, 132, 1809-1816.
53. Melis, M., Pistis, M., Perra, S., Muntoni, A.L., Pillolla, G., & Gessa, G.L. (2004). Endocannabinoids mediate presynaptic inhibition of glutamatergic transmission in rat ventral tegmental area dopamine neurons through activation of CB1 receptors. Journal of Neuroscience, 24, 53-62.
54. Merritt, L.L., Martin, B.R., Walters, C., Lichtman, A.H., & Damaj, M.I. (2008). The endogenous cannabinoid system modulates nicotine reward and dependence. Journal of Pharmacology and Experimental Therapeutics, 326, 483-492.
55. Navarro, M., Carrera, M.R., Del Arco, I., Trigo, J.M., Koob, G.F., & Rodriguez de Fonseca, F. (2004). Cannabinoid receptor antagonist reduces heroin selfadministration only in dependent rats. European Journal of Pharmacology, 501, 235-237.
56. Navarro, M., Carrera, M.R., Fratta, W., Valverde, O., Cossu, G., Fattore, L. et al. (2001). Functional interaction between opioid and cannabinoid receptors in drug self-administration. Journal of Neuroscience, 21, 5344-5350.
57. Nowak, K.L., Vinod, K.Y., & Hungund, B.L. (2006). Pharmacological manipulation of CB1 receptor function alters development of tolerance to alcohol. Alcohol and Alcoholism, 41, 24-32.
58. Rinaldi-Carmona, M., Barth, F., Congy, C., Martinez, S., Oustric, D., Perio, A. et al. (2004). SR147778 [5-(4-bromophenyl)-1-(2, 4-dichlorophenyl)-4- ethyl-N-(1-piperidinyl)-1H-pyrazole-3-carboxamide], a new potent and selective antagonist of the CB1 cannabinoid receptor: Biochemical and pharmacological characterization. Journal of Pharmacology and Experimental Therapeutics, 310, 905-914.
59. Rinaldi-Carmona, M., Barth, F., Heaulme, M., Shire, D., Calandra, B., Congy, C., Martinez, S., Maruani, J., Neliat, G., Caput, D. et al. (1994). SR141716A, a potent and selective antagonist of the brain cannabinoid receptor. Federation of European Biochemical Societies Letters, 350, 240-244.
60. Rodriguez de Fonseca, F., Roberts, A.J., Bilbao, A., Koob, G.F., & Navarro, M. (1999). Cannabinoid receptor antagonist SR141716A decreases operant ethanol self administration in rats exposed to ethanol-vapor chambers. Zhongguo Yao Li Xue Bao, 20, 1109-1114.
61. Rubino, T., Vigano, D., Zagato, E., Sala, M., & Parolaro, D. (2000). In vivo characterization of the specific cannabinoid receptor antagonist, SR141716A: Behavioral and cellular responses after acute and chronic treatments. Synapse, 35, 8-14.
62. Serra, S., Brunetti, G., Pani, M., Vacca, G., Carai, M.A., Gessa, G.L. et al. (2002). Blockade by the cannabinoid CB(1) receptor antagonist, SR 141716, of alcohol deprivation effect in alcohol-preferring rats. European Journal of Pharmacology, 443, 95-97.
63. Serra, S., Carai, M.A., Brunetti, G., Gomez, R., Melis, S., Vacca, G. et al. (2001). The cannabinoid receptor antagonist SR 141716 prevents acquisition of drinking behavior in alcoholpreferring rats. European Journal of Pharmacology, 430, 369-371.
64. Shoaib, M. (2008). The cannabinoid antagonist AM251 attenuates nicotine self-administration and nicotine-seeking behaviour in rats. Neuropharmacology, 54, 438-444.
65. Singh, M.E., Verty, A.N., McGregor, I.S., & Mallet, P.E. (2004). A cannabinoid receptor antagonist attenuates conditioned place preference but not behavioural sensitization to morphine. Brain Research, 1026, 244-253.
66. Solinas, M., Justinova, Z., Goldberg, S.R., & Tanda, G. (2006). Anandamide administration alone and after inhibition of fatty acid amide hydrolase (FAAH) increases dopamine levels in the nucleus accumbens shell in rats. Journal of Neurochemistry, 98, 408-419.
67. Solinas, M., Panlilio, L.V., Antoniou, K., Pappas, L.A., & Goldberg, S.R. (2003). The cannabinoid CB1 antagonist N-piperidinyl-5-(4-chlorophenyl)-1- (2, 4-dichlorophenyl)-4-methylpyrazole-3-carboxamide (SR-141716A) differentially alters the reinforcing effects of heroin under continuous reinforcement, fixed ratio, and progressive ratio schedules of drug self-administration in rats. Journal of Pharmacology and Experimental Therapeutics, 306, 93-102.
68. Solinas, M., Scherma, M., Tanda, G., Wertheim, C.E., Fratta, W., & Goldberg, S.R. (2007). Nicotinic facilitation of delta9-tetrahydrocannabinol discrimination involves endogenous anandamide. Journal of Pharmacology and Experimental Therapeutics, 321, 1127-1134.
69. Soria-Gomez, E., Matias, I., Rueda-Orozco, P.E., Cisneros, M., Petrosino, S., Navarro, L. et al. (2007). Pharmacological enhancement of the endocannabinoid system in the nucleus accumbens shell stimulates food intake and increases c-Fos expression in the hypothalamus. British Journal of Pharmacology, 151, 1109-1116.
70. Soyka, M., Koller, G., Schmidt, P., Lesch, O.M., Leweke, M., Fehr, C. et al. (2008). Cannabinoid receptor 1 blocker rimonabant (SR 141716) for treatment of alcohol dependence: Results from a placebo-controlled, double-blind trial. Journal of Clinical Psychopharmacology, 28, 317-324.
71. Tanda, G., Munzar, P., & Goldberg, S.R. (2000). Self-administration behavior is maintained by the psychoactive ingredient of marijuana in squirrel monkeys. Nature & Neuroscience, 3, 1073-1074.
72. Vinklerová, J., Nováková, J., & Šulcová, A. (2002). Inhibition of methamphetamine self-administration in rats by cannabinoid receptor antagonist AM 251. Journal of Psychopharmacology, 16, 139-143.
73. Vinod, K.Y., Yalamanchili, R., Thanos, P.K., Vadasz, C., Cooper, T.B., Volkow, N.D. et al. (2008). Genetic and pharmacological manipulations of the CB(1) receptor alter ethanol preference and dependence in ethanol preferring and nonpreferring mice. Synapse, 62, 574-581.
74. Xi, Z.X., Gilbert, J.G., Peng, X.Q., Pak, A.C., Li, X., & Gardner, E.L. (2006). Cannabinoid CB1 receptor antagonist AM251 inhibits cocaine-primed relapse in rats: Role of glutamate in the nucleus accumbens. Journal of Neuroscience, 26, 8531-8536.
75. Xi, Z.X., Spiller, K., Pak, A.C., Gilbert, J., Dillon, C., Li, X. et al. (2008). Cannabinoid CB1 receptor antagonists attenuate cocaine's rewarding effects: Experiments with selfadministration and brain-stimulation reward in rats. Neuropsychopharmacology, 33, 1735-1745.
76. Zaniewska, M., McCreary, A.C., Przegalinski, E., & Filip, M. (2006). Evaluation of the role of nicotinic acetylcholine receptor subtypes and cannabinoid system in the discriminative stimulus effects of nicotine in rats. European Journal of Pharmacology, 540, 96-106.